




Searching News Database: HSDD
HSMN NewsFeed - 20 Aug 2015
S1 Biopharma Supports FDA Approval of First-Ever Treatment for Hypoactive Sexual Desire Disorder
S1 Biopharma Supports FDA Approval of First-Ever Treatment for Hypoactive Sexual Desire Disorder
HSMN NewsFeed - 4 Oct 2012
BioSante Pharmaceuticals and ANI Pharmaceuticals Announce Merger Agreement
BioSante Pharmaceuticals and ANI Pharmaceuticals Announce Merger Agreement
HSMN NewsFeed - 24 Apr 2012
S1 Pharmaceuticals Announces New Executive Management and Scientific Advisory Board Appointments
S1 Pharmaceuticals Announces New Executive Management and Scientific Advisory Board Appointments
HSMN NewsFeed - 8 Mar 2012
S1 Pharmaceuticals Announces New Executive Management and Scientific Advisory Board Appointments
S1 Pharmaceuticals Announces New Executive Management and Scientific Advisory Board Appointments
HSMN NewsFeed - 14 Feb 2011
BioSante Pharmaceuticals Reports Positive LibiGel(R) Safety Data in Phase III Program
BioSante Pharmaceuticals Reports Positive LibiGel(R) Safety Data in Phase III Program
HSMN NewsFeed - 26 Mar 2010
VIVUS Announces Date of FDA Advisory Committee Review of Qnexa(R) for the Treatment of Obesity
VIVUS Announces Date of FDA Advisory Committee Review of Qnexa(R) for the Treatment of Obesity
HSMN NewsFeed - 29 Dec 2009
VIVUS Submits Qnexa(R) New Drug Application to the FDA for the Treatment of Obesity
VIVUS Submits Qnexa(R) New Drug Application to the FDA for the Treatment of Obesity
HSMN NewsFeed - 30 Jun 2009
BioSante Pharmaceuticals and Cell Genesys Sign Definitive Merger Agreement
BioSante Pharmaceuticals and Cell Genesys Sign Definitive Merger Agreement
HSMN NewsFeed - 7 May 2009
Results From Phase 3 EQUATE Trial of VIVUS' Qnexa Highlighted at European Congress on Obesity
Results From Phase 3 EQUATE Trial of VIVUS' Qnexa Highlighted at European Congress on Obesity
HSMN NewsFeed - 15 Apr 2008
BioSante Pharmaceuticals Appoints Michael C. Snabes, M.D., PhD, Vice President, Clinical Development
BioSante Pharmaceuticals Appoints Michael C. Snabes, M.D., PhD, Vice President, Clinical Development
HSMN NewsFeed - 29 Jan 2008
BioSante Pharmaceuticals Announces FDA Special Protocol Assessment (SPA) for LibiGel(R) in FSD
BioSante Pharmaceuticals Announces FDA Special Protocol Assessment (SPA) for LibiGel(R) in FSD
HSMN NewsFeed - 30 Jul 2007
KV Pharmaceutical Announces U.S. Food and Drug Administration Approval of EvaMist(TM)
KV Pharmaceutical Announces U.S. Food and Drug Administration Approval of EvaMist(TM)
HSMN NewsFeed - 21 Jun 2007
VIVUS Completes End of Phase 2 Meeting with the FDA for Qnexa, a Treatment for Obesity
VIVUS Completes End of Phase 2 Meeting with the FDA for Qnexa, a Treatment for Obesity
HSMN NewsFeed - 16 May 2007
KV Pharmaceutical Company Completes Acquisition of U.S. Rights to EvaMist(TM)
KV Pharmaceutical Company Completes Acquisition of U.S. Rights to EvaMist(TM)
HSMN NewsFeed - 1 Nov 2006
VIVUS Appoints Changjin (CJ) Wang, Ph.D. as Vice President of Business Development
VIVUS Appoints Changjin (CJ) Wang, Ph.D. as Vice President of Business Development
HSMN NewsFeed - 19 May 2006
Novavax and Esprit Pharma to Co-develop Novel Medicine for Female Sexual Desire Disorder
Novavax and Esprit Pharma to Co-develop Novel Medicine for Female Sexual Desire Disorder
HSMN NewsFeed - 10 May 2006
VIVUS Announces Positive Phase 2 Clinical Trial Results With Qnexa, a Novel Therapy to Treat Obesity
VIVUS Announces Positive Phase 2 Clinical Trial Results With Qnexa, a Novel Therapy to Treat Obesity
Additional items found! 10

Members Archive contains
10 additional stories matching:
HSDD
(Password required)
HSDD
(Password required)